HemaSphere (Aug 2023)
P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS
- Wei Xu,
- Ru Feng,
- LI Wang,
- Huayuan Zhu,
- Keshu Zhou,
- Xiaorui Fu,
- Hongmei Jing,
- Yuqin Song,
- Junyuan Qi,
- Guohui Cui,
- Fei LI,
- Shaoyuan Wang,
- Hui Zhou,
- Wenbin Qian,
- Qingqing Cai,
- Xielan Zhao,
- Xutao Guo,
- Xiaolei Wei,
- Ningjing Lin,
- Zhongyuan Xu,
- Zheng Wang,
- Xiang Xiao,
- Jiale Dong,
- Yejiang Lou,
- Yue Shen,
- Yi Chen,
- Yu Chen,
- Fenlai Tan,
- Stephen Anthony,
- Jianyong LI
Affiliations
- Wei Xu
- 1 The First Affiliated Hospital of Nanjing Medical University, Department of Hematology, Nanjing, China
- Ru Feng
- 2 Nanfang Hospital of Southern Medical University, Department of Hematology, Guangzhou, China
- LI Wang
- 1 The First Affiliated Hospital of Nanjing Medical University, Department of Hematology, Nanjing, China
- Huayuan Zhu
- 1 The First Affiliated Hospital of Nanjing Medical University, Department of Hematology, Nanjing, China
- Keshu Zhou
- 3 Henan Cancer Hospital, Department of Hematology, Zhengzhou, China
- Xiaorui Fu
- 4 The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Zhengzhou, China
- Hongmei Jing
- 5 Peking University Third Hospital, Beijing, Department of Hematology, Beijing, China
- Yuqin Song
- 6 Beijing Cancer Hospital, Department of Lymphoma, Beijing, China
- Junyuan Qi
- 7 Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
- Guohui Cui
- 8 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Hematology, Wuhan, China
- Fei LI
- 9 The First Affiliated Hospital of Nanchang University, Department of Hematology, Nanchang, China
- Shaoyuan Wang
- 10 Fujian Medical University Union Hospital, Department of Hematology, Fuzhou, China
- Hui Zhou
- 11 Hunan Cancer Hospital, Department of Lymphoma and Hematology, Changsha, China
- Wenbin Qian
- 12 The Second Affiliated Hospital Zhejiang University School of Medicine, Department of Hematology, Hangzhou, China
- Qingqing Cai
- 13 Sun Yat-sen University Cancer Center, Department of Medical Oncology, Guangzhou, China
- Xielan Zhao
- 14 Xiangya Hospital, Central South University, Department of Hematology, Changsha, China
- Xutao Guo
- 2 Nanfang Hospital of Southern Medical University, Department of Hematology, Guangzhou, China
- Xiaolei Wei
- 2 Nanfang Hospital of Southern Medical University, Department of Hematology, Guangzhou, China
- Ningjing Lin
- 6 Beijing Cancer Hospital, Department of Lymphoma, Beijing, China
- Zhongyuan Xu
- 15 Nanfang Hospital of Southern Medical University, Phase I Unit, Guangzhou, China
- Zheng Wang
- 16 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China
- Xiang Xiao
- 16 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China
- Jiale Dong
- 16 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China
- Yejiang Lou
- 16 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China
- Yue Shen
- 16 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China
- Yi Chen
- 17 Newave Pharmaceutical Inc., Pleasanton, United States
- Yu Chen
- 17 Newave Pharmaceutical Inc., Pleasanton, United States
- Fenlai Tan
- 16 Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China
- Stephen Anthony
- 17 Newave Pharmaceutical Inc., Pleasanton, United States
- Jianyong LI
- 1 The First Affiliated Hospital of Nanjing Medical University, Department of Hematology, Nanjing, China
- DOI
- https://doi.org/10.1097/01.HS9.0000969444.32459.0c
- Journal volume & issue
-
Vol. 7
p. e324590c
Abstract
No abstracts available.
